Cellwise(SH:688325)2022-10-25 16:00Financial Performance - The company's operating revenue for Q3 2022 was ¥35,706,264.73, a decrease of 56.73% compared to the same period last year[5]. - The net profit attributable to shareholders was -¥2,121,777.67, reflecting a decline of 110.62% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥2,426,730.72, down 112.03% from the previous year[5]. - Total operating revenue for the first three quarters of 2022 was CNY 144,681,157.92, a decrease of 41.2% compared to CNY 246,447,175.58 in the same period of 2021[22]. - Net profit for the first three quarters of 2022 was CNY 25,606,047.13, a decline of 58.8% compared to CNY 62,031,206.42 in the same period of 2021[23]. - The total comprehensive income attributable to the parent company for Q3 2022 was CNY 25,551,572.13, compared to CNY 62,035,790.50 in Q3 2021, representing a decrease of approximately 58.8%[24]. - Basic earnings per share for Q3 2022 were CNY 0.36, down from CNY 1.03 in Q3 2021, indicating a decline of about 65.5%[24]. Cash Flow and Liquidity - The cash flow from operating activities for the year-to-date was -¥18,159,910.67, a decrease of 117.87%[6]. - Cash flow from operating activities for the first three quarters of 2022 was CNY 190,509,472.88, a decrease of 31.2% from CNY 277,057,731.23 in the same period of 2021[26]. - The net cash flow from operating activities for Q3 2022 was negative CNY 18,159,910.67, compared to a positive CNY 101,634,877.80 in Q3 2021[26]. - The company reported cash inflow from investment activities of CNY 482,436,997.73 in the first three quarters of 2022, with cash outflow of CNY 904,423,159.73, resulting in a net cash flow of negative CNY 421,986,162.00[26]. - Cash flow from financing activities for the first three quarters of 2022 was CNY 1,374,005,583.64, significantly higher than CNY 14,963,871.18 in the same period of 2021[27]. - The net increase in cash and cash equivalents for Q3 2022 was CNY 919,121,179.34, compared to CNY 100,837,263.50 in Q3 2021, indicating a substantial increase[27]. - The ending balance of cash and cash equivalents as of the end of Q3 2022 was CNY 1,116,523,895.14, up from CNY 175,932,193.34 at the end of Q3 2021[27]. - The company received CNY 480,000,000.00 from the recovery of investments during Q3 2022[26]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,672,080,486.88, an increase of 467.73% compared to the end of the previous year[6]. - Total liabilities as of the end of the third quarter of 2022 were CNY 54,212,914.76, a decrease from CNY 68,862,233.93 in the previous year[19]. - Total equity attributable to shareholders was CNY 1,617,867,572.12, significantly higher than CNY 225,659,250.83 in the previous year[19]. - The total current assets reached ¥1,625,473,557.59, compared to ¥274,659,076.04 in the previous year, indicating substantial growth[17]. - Inventory levels increased to ¥87,998,440.61 from ¥44,107,867.83, reflecting a rise of approximately 99.5% year-over-year[17]. - The company reported accounts receivable of ¥7,850,329.18, down from ¥18,456,967.92, showing a decrease of about 57.5%[17]. Research and Development - Research and development expenses totaled ¥17,727,672.46, accounting for 49.65% of operating revenue, an increase of 28.83 percentage points[6]. - Research and development expenses for the first three quarters of 2022 amounted to CNY 50,064,412.33, slightly up from CNY 49,808,328.25 in the previous year[22]. Market and Strategic Outlook - The decline in operating revenue was primarily due to market cooling and the impact of the pandemic on business expansion and product launches[10]. - The company plans to stabilize its supply chain by securing important raw materials, which has led to increased procurement expenses[10]. - The company is actively involved in market expansion and new product development, although specific details were not provided in the conference call[16]. - Future outlook remains optimistic, with ongoing strategies for technological advancements and potential mergers and acquisitions being discussed[16]. - The company plans to focus on market expansion and new product development in the upcoming quarters to drive growth[22]. Shareholder Information - The total number of shareholders at the end of the reporting period was not specified, but the top ten shareholders held significant stakes, with the largest being Dongguan Weitu Investment at 22.01%[13]. - The company has a total of 818,341 restricted shares, representing 1.02% of the total shares, which will become tradable on October 24, 2022[15]. - The company has a diverse shareholder base, with several investment funds and partnerships holding significant shares, indicating strong institutional interest[14]. Audit and Compliance - The financial report did not indicate any audit opinion type, suggesting that the financial statements are unaudited[16].